Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Phys Chem Chem Phys ; 16(42): 23379-85, 2014 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-25263001

RESUMEN

Fluorine and carbon K absorption and emission spectra of liquid perfluorodecalin are presented and analyzed in terms of density functional calculations-configuration interaction. A comprehensive view of the electronic structure is given, and site-specific intramolecular interactions are investigated in detail. It is found that, while the outer fluorine atoms have excess charge in the ground state, the lowest excitations must be associated with charge transfer towards the inner carbon atoms.


Asunto(s)
Electrones , Fluorocarburos/química , Carbono/química , Flúor/química , Estructura Molecular , Teoría Cuántica , Espectroscopía de Absorción de Rayos X
2.
Inn Med (Heidelb) ; 64(8): 758-765, 2023 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-37462691

RESUMEN

"Diseases of the thyroid gland occur more frequently in women": this statement has been used in textbooks for decades; however, is this equally true for all thyroid gland diseases and can conclusions be derived from this for a different disease relevance and prognosis in men and women? Is possibly even a sex-specific treatment needed? These questions are taken up and subsequently the epidemiological data and studies that have investigated the influence of gender on the course of thyroid gland diseases are taken into consideration. It is shown that the data situation is much more restricted than is to be expected for frequent diseases in the general population.


Asunto(s)
Hipotiroidismo , Enfermedades de la Tiroides , Masculino , Humanos , Femenino , Hipotiroidismo/epidemiología , Enfermedades de la Tiroides/diagnóstico
3.
Chirurgie (Heidelb) ; 94(1): 79-92, 2023 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-36121448

RESUMEN

The increase in small intrathyroid papillary thyroid cancer (PTC) observed worldwide over the past two decades, with no increase in cancer-specific mortality, has challenged the previous concept of total thyroidectomy as a one-size-fits-all panacea. After exclusion of papillary microcarcinomas, a systematic review of 20 clinical studies published since 2002, which compared hemithyroidectomy (HT) to total thyroidectomy (TT), found comparable long-term oncological outcomes for low-risk papillary thyroid cancer (LRPTC) 1-4 cm in diameter, whereas postoperative complication rates were markedly lower for HT. To refine individual treatment plans, HT should be combined with ipsilateral central lymph node dissection and intraoperative frozen section analysis for staging. Based on recent evidence from studies and in consideration of individual risk factors, patients with LRPTC can be offered the concept of HT as an alternative to the standard TT. A prerequisite for the treatment selection and decision is a comprehensive patient clarification of the possible advantages and disadvantages of both approaches.


Asunto(s)
Carcinoma Papilar , Neoplasias de la Tiroides , Humanos , Tiroidectomía/efectos adversos , Cáncer Papilar Tiroideo/cirugía , Neoplasias de la Tiroides/cirugía , Neoplasias de la Tiroides/patología , Carcinoma Papilar/cirugía , Carcinoma Papilar/patología , Riesgo
4.
Endocr Connect ; 10(3): 283-289, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33617464

RESUMEN

Medullary thyroid carcinomas (MTC) are rare and aggressive neuroendocrine tumors of the thyroid. About 70% of MTC are sporadic; approximately 50% of those harbor somatic RET mutation. DLL3 is widely expressed in many neuroendocrine tumors and has been evaluated as a potential therapeutic target. Since stromal desmoplasia in sporadic MTC has been identified as a reliable predictor of aggressive behavior and development of lymph node metastases, a possible correlation of DLL3 expression with the presence of stromal desmoplasia was of particular interest. 59 paraffin-embedded samples of sporadic MTC with (44 cases) and without (15 cases) stromal desmoplasia and known lymph node status were included. DLL3 expression was determined by immunohistochemistry; no expression (0%), low expression (1-49%) and high expression (≥50%) were correlated with clinicopathological data. The proportion of DLL3 positivity was significantly correlated with both stromal desmoplasia (P < 0.0001) and lymph node metastases (P < 0.0001). MTC without stromal desmoplasia consistently lack DLL3 expression. This is the first study to focus on MTC regarding DLL3 expression and the relationship to various factors. Our results demonstrate that expression of DLL3 in MTC represents a reliable surrogate marker for stromal desmoplasia and lymph node metastases and might be an indicator for aggressive clinical behavior. DLL3 expression in ≥50% of tumor cells virtually excludes MTC without stromal desmoplasia. DLL3 was discussed as a potential therapeutic target in malignant tumors of other locations with positive immunohistochemical reaction and might therefore be a new therapeutic option in MTC, as well.

5.
Chirurg ; 91(12): 1038-1043, 2020 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-33025108

RESUMEN

The treatment of radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) remains challenging. Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive thyroid cancer in Germany. The indications for starting systemic treatment remain a challenge as the diseases can be stable and asymptomatic over long periods of time. In contrast, MKI treatment, which slows the disease progression but is not curative, is often associated with side effects that can impair quality of life. For this reason, an aim is to develop more specific treatments with low off-target effects. In this context selective RET kinase inhibitors represent a promising new approach, which is currently tested intensively in clinical trials, e.g. for advanced symptomatic MTC.


Asunto(s)
Antineoplásicos , Carcinoma Neuroendocrino , Neoplasias de la Tiroides , Antineoplásicos/uso terapéutico , Alemania , Humanos , Radioisótopos de Yodo/uso terapéutico , Calidad de Vida , Neoplasias de la Tiroides/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA